Ideaya Biosciences Stock Jumps on Promising Eye Cancer Treatment Results
Ideaya Biosciences shares rise after reporting breakthrough survival data for rare eye cancer treatment combining darovasertib with Pfizer's Xalkori in clinical trial.
Ideaya Biosciences shares rise after reporting breakthrough survival data for rare eye cancer treatment combining darovasertib with Pfizer's Xalkori in clinical trial.
IDE849, a new DLL3-targeting drug for SCLC, shows strong efficacy with high response rates (up to 77.1%) and activity in brain metastases. It has a manageable safety profile, offering new hope for patients.